Zynex (NASDAQ:ZYXI) Issues Quarterly Earnings Results

Zynex (NASDAQ:ZYXI) posted its quarterly earnings data on Tuesday. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.11), Zacks reports. Zynex had a return on equity of 13.05% and a net margin of 2.49%.

Zynex Stock Performance

Shares of NASDAQ ZYXI traded down $0.17 during trading hours on Tuesday, reaching $7.00. The stock had a trading volume of 103,825 shares, compared to its average volume of 112,056. The firm has a 50-day moving average of $7.74 and a 200-day moving average of $8.02. The firm has a market cap of $222.92 million, a price-to-earnings ratio of 46.67 and a beta of 0.81. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. Zynex has a fifty-two week low of $5.44 and a fifty-two week high of $13.19.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Zynex in a research report on Friday, December 6th.

Insider Transactions at Zynex

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.15, for a total value of $71,500.00. Following the transaction, the chief financial officer now owns 10,050 shares in the company, valued at $71,857.50. The trade was a 49.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 30,000 shares of company stock worth $227,100. Insiders own 52.13% of the company’s stock.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.